ImmunityBio Inc. (NASDAQ:IBRX) saw its stock price climb significantly on Friday, extending gains for an eleventh consecutive session. The rally pushed the stock to a new 52-week high during intra-day trading, reaching $5.58 before closing at $5.52, up 39.75 percent for the session.
The company attributed the movement to several recent developments. ImmunityBio announced that its CD19 CAR-NK treatment, used with rituximab, showed full disease control in four patients. Two of these patients achieved complete remission at 7 and 15 months without needing further treatment after the initial eight doses.
In a statement, the company said tumors disappeared completely after only two cycles. It noted that the durability of the response after treatment ended highlights potential for long-term immune-mediated disease control without continuous therapy.
Separately, ImmunityBio reported preliminary revenues for Anktiva reached $113 million for the full-year 2025, representing a 700 percent increase. The company cited strong demand. It also received approval from Saudi Arabia's Food and Drug Administration to sell and market Anktiva, paving the way for expansion into that market.
The stock's performance on Friday followed its inclusion in a recent list of top-performing firms.